Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC24A3 antisense RNA 2 (SLC24A3-AS2) is a long non-coding RNA transcribed from the opposite strand of the SLC24A3 gene locus. Antisense RNAs are typically involved in the regulation of their associated sense genes through a variety of mechanisms, including transcriptional interference, RNA-RNA duplex formation, and modulation of epigenetic states[1][2]. The specific function or biological roles of SLC24A3-AS2 have not been characterized in detail in humans; it is annotated as a novel transcript antisense to SLC24A3[3][7]. SLC24A3 itself encodes a sodium/potassium/calcium exchanger important in cellular calcium regulation, but SLC24A3-AS2 is a non-coding transcript. Notes on accuracy and ambiguity - is_incorrect: true — There is no evidence that "SLC24A3-AS2" itself is a conventional therapeutic target (such as a receptor, transporter, enzyme, etc.), nor is it currently described as a disease biomarker, drug target, or known to interact with drugs[3][7]. - Gene annotation: SLC24A3-AS2 is an RNA gene, not a protein-coding gene, and functions (if any) are consistent with general properties of antisense lncRNAs[1][2]. - Aliases: GeneCards lists "ENSG00000232675" as a novel transcript antisense to SLC24A3[3][7]. - Description: Due to absence of direct experimental data on SLC24A3-AS2, biological functions and disease involvement are inferred solely from the properties of similar antisense lncRNAs[1][2]. If you seek information on the protein-coding gene "SLC24A3" (Solute carrier family 24 member 3), it encodes a sodium/potassium/calcium exchanger membrane protein, but this is distinct from the lncRNA SLC24A3-AS2[6][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SLC24A3 antisense RNA 2 (SLC24A3-AS2).